News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Advanced Viral Research Corp. Shares Progress of AVR118 Phase II Cancer Cachexia Study at McGill University
April 1, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
YONKERS, NY--(Marketwire - April 01, 2008) - Advanced Viral Research Corp. (OTCBB: ADVR) announced today that enrollment for its Phase II efficacy study for AVR118 in cancer cachexia is progressing in line with expectations.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
MORE ON THIS TOPIC
Cancer
Kura’s encouraging cancer drug data could unlock $2B market opportunity
May 27, 2026
·
2 min read
·
Tristan Manalac
Insights
Germany can produce biotech winners. Europe must back them better.
May 27, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Manufacturing
Niowave, fresh from Novartis deal, starts building $75M radioisotope plant
May 26, 2026
·
2 min read
·
Nick Paul Taylor
Gene editing
Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study
May 26, 2026
·
2 min read
·
Tristan Manalac
